Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market

Research and Markets (http://www.researchandmarkets.com/reports/c92947) has announced the addition of “Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market” to their offering.

Introduction

Although the obsessive-compulsive disorder (OCD) market is small and OCD diagnosis rates are low, this market is characterized by substantial unmet need and commercial opportunity. Companies looking to expand their agents into this market need to explore unconventional strategies that will minimize the resources necessary to ensure success in OCD.

Get the Answers You Need to Shape Your Strategy

– Despite the high use of drug therapy in the treatment of OCD, 40-60% of patients do not achieve sufficient relief from their symptoms. What opportunities does this unmet need present to developers? Are any agents now in development likely to meet this need?

– Due to the large percentage of patients who are not sufficiently treated with available approved agents, psychiatrists often prescribe off-label agents to treat OCD. How well do these off-label agents perform in the OCD market? Will pending guidance from the FDA regarding the distribution of data from clinical trials in off-label indications help companies increase their market share for off-label treatments?

– Although there are few agents in commercial development for OCD, there are agents being investigated for their efficacy in OCD by research and medical organizations. What does the possible influx of a large number of new agents to treat OCD mean for currently available treatments? How can emerging agents differentiate themselves from other current and emerging agents?

Scope

– Overview of OCD: symptoms and diagnosis, etiology.

– Epidemiology: Decision Resources estimates of the number of prevalent cases of OCD in the major markets over 2007-2017 and the number of diagnosed and drug-treated cases in the major markets in 2007.

– Treatment algorithms: a treatment decision tree, a listing of currently used agents, and profiles of leading agents.

– Use of off-label agents: discussion of agents commonly used off-label, physician attitudes toward off-label use, pending FDA proposals to broaden marketing of these agents.

– OCD market: 2007 sales figures, current market dynamics, strategies for maximizing market potential.

Companies Mentioned:

– Astellas

– AstraZeneca

– Boehringer Ingelheim

– Bristol-Myers Squibb

– Elan

– Eli Lilly

– Forest Laboratories

– GlaxoSmithKline

– Janssen

– Johnson & Johnson

– Merck

– Neuropharm

– Novartis

– Otsuka Pharmaceuticals

– Pfizer

– Sanofi -Aventis

– Solvay

– UCB

– Wyeth

– Zambon

For more information, visit http://www.researchandmarkets.com/reports/c92947